Parkin in the regulation of fat uptake and mitochondrial biology: Emerging links in the pathophysiology of Parkinson's disease

Current Opinion in Lipidology

Volumn 23, Issue 3, 2012, Pages 201-205

  Kim, Kye Young ^a   Sack, Michael N ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

CD36; fat uptake; Parkin; peroxisome proliferator activated receptor gamma coactivator 1 alpha

Indexed keywords

CD36 ANTIGEN; FAT; FATTY ACID; PARKIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA;

ENZYME ACTIVITY; GENETIC RISK; HUMAN; LIPID METABOLISM; LIPID TRANSPORT; MITOCHONDRION; MITOPHAGY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK FACTOR;

ANIMALS; BIOLOGICAL TRANSPORT; BRAIN; FATTY ACIDS; HUMANS; MITOCHONDRIA; PARKINSON DISEASE; UBIQUITIN-PROTEIN LIGASES;

EID: 84861101160     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328352dc5d     Document Type: Review

References (35)

1. Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med 2010; 16:653-661.
2. Ahlskog JE. Parkin and PINK1 parkinsonism may represent nigral mitochon-drial cytopathies distinct from Lewy body Parkinson's disease. Parkinsonism Relat Disord 2009; 15:721-727.
3. Zheng B, Liao Z, Locascio JJ, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010; 2:52ra73.
4. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003; 24:78-90. (Pubitemid 36223280)
5. Summermatter S, Baum O, Santos G, et al. Peroxisome proliferator- activated receptor {gamma} coactivator 1{alpha} (PGC-1{alpha}) promotes skeletal muscle lipid refueling in vivo by activating de novo lipogenesis and the pentose phosphate pathway. J Biol Chem 2010; 285:32793-32800.
6. Bazan NG, Molina MF, Gordon WC. Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu Rev Nutr 2011; 31:321-351.
7. Lauritzen L, Hansen HS, Jorgensen MH, Michaelsen KF. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog Lipid Res 2001; 40:1-94. (Pubitemid 32008650)
8. Houtkooper RH, Vaz FM. Cardiolipin, the heart of mitochondrial metabolism. Cell Mol Life Sci 2008; 65:2493-2506.
9. Owada Y. Fatty acid binding protein: localization and functional significance in the brain. Tohoku J Exp Med 2008; 214:213-220. (Pubitemid 351513533)
10. Mitchell RW, On NH, Del Bigio MR, et al. Fatty acid transport protein expression in human brain and potential role in fatty acid transport across human brain microvessel endothelial cells. J Neurochem 2011; 117:735-746.
11. Song BJ, Elbert A, Rahman T, et al. Genetic ablation of CD36 does not alter mouse brain polyunsaturated fatty acid concentrations. Lipids 2010; 45:291-299.
12. Huang X, Abbott RD, Petrovitch H, et al. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov Disord 2008; 23:1013-1018.
13. de Lau LM, Bornebroek M, Witteman JC, et al. Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology 2005; 64:2040-2045. (Pubitemid 40880989)
14. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol 2006; 164:998-1002. (Pubitemid 44729842)
15. Bousquet M, Calon F, Cicchetti F. Impact of omega-3 fatty acids in Parkinson's disease. Ageing Res Rev 2011; 10:453-463.
16. Assayag K, Yakunin E, Loeb V, et al. Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. Am J Pathol 2007; 171:2000-2011.
17. Sharon R, Bar-Joseph I, Mirick GE, et al. Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem 2003; 278:49874-49881. (Pubitemid 37548822)
18. Lim KL, Chew KC, Tan JM, et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 2005; 25:2002-2009. (Pubitemid 40289405)
19. Fallon L, Belanger CM, Corera AT, et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol 2006; 8:834-842. (Pubitemid 44151586)
20. Xiong H, Wang D, Chen L, et al. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 2009; 119:650-660.
21. Moore DJ, West AB, Dikeman DA, et al. Parkin mediates the degradation-independent ubiquitination of Hsp70. J Neurochem 2008; 105:1806-1819. (Pubitemid 351678490)
22. da Costa CA, Sunyach C, Giaime E, et al. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol 2009; 11:1370-1375.
23. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008; 183:795-803.
24. Geisler S, Holmstrom KM, Skujat D, et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 2010; 12:119-131.
25. Li H, Guo M. Protein degradation in Parkinson disease revisited: it's complex. J Clin Invest 2009; 119:442-445.
26. Abumrad NA, Moore DJ. Parkin reinvents itself to regulate fatty acid metabolism by tagging CD36. J Clin Invest 2011; 121:3389-3392.
27. PesahY, Pham T, Burgess H,et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 2004; 131:2183-2194. (Pubitemid 38702049)
28. Goldberg MS, Fleming SM, Palacino JJ, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003; 278:43628-43635. (Pubitemid 37345989)
29. Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci USA 2005; 102:2174-2179. (Pubitemid 40262031)
30. Kitada T, Tong Y, Gautier CA, Shen J. Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. J Neurochem 2009; 111:696-702.
31. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011; 12:9-14.
32. Palacino JJ, Sagi D, Goldberg MS, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004; 279: 18614-18622. (Pubitemid 38623283)
33. Kim KY, Stevens MV, Akter MH, et al. Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. J Clin Invest 2011; 121:3701-3712.
34. Shin JH, Ko HS, Kang H, et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011; 144: 689-702.
35. Pacelli C, De Rasmo D, Signorile A, et al. Mitochondrial defect and PGC-1alpha dysfunction in parkin-associated familial Parkinson's disease. Biochim Biophys Acta 2011; 1812:1041-1053.